MiNK Therapeutics

MiNK Therapeutics is at the forefront of developing novel, allogeneic iNKT cell therapies, a promising class of living medicines. The company's platform is designed to overcome key limitations of traditional cell therapies by offering an 'off-the-shelf' product that does not require patient matching or preconditioning. With over 70 patients treated across its programs in solid tumors and severe ARDS, MiNK has demonstrated initial clinical proof-of-concept and is now focused on advancing its pipeline and scaling its manufacturing technology. Its strategic direction involves leveraging the unique biology of iNKT cells for both oncology and inflammatory diseases.

Proprietary platform for developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies. The platform leverages iNKT cells' unique ability to bridge innate and adaptive immunity without causing graft-versus-host disease, enabling administration without HLA matching or lymphodepletion.

3 drugs in pipeline

Competes in the allogeneic cell therapy space against companies developing CAR-T (e.g., Allogene) and NK cell therapies. Differentiates through its focus on iNKT cells, which offer a potentially superior safety profile (low GvHD risk) and dual mechanism of action. Also a first-mover in applying cell therapy to ARDS.